Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Cresco Labs ( (TSE:CL) ) is now available.
Cresco Labs reported strong financial results for the third quarter of 2025, with a revenue of $165 million and an adjusted EBITDA of $40 million. The company successfully refinanced its debt, strengthening its balance sheet and extending debt maturity to 2030. Cresco Labs is expanding its operations with new dispensaries in Ohio, entering the Kentucky market, and planning a product launch in Germany, positioning itself for future growth and market leadership.
The most recent analyst rating on (TSE:CL) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Cresco Labs stock, see the TSE:CL Stock Forecast page.
Spark’s Take on TSE:CL Stock
According to Spark, TipRanks’ AI Analyst, TSE:CL is a Neutral.
Cresco Labs’ overall stock score is primarily impacted by its financial performance, which is challenged by declining revenues, high leverage, and negative profitability. Technical analysis suggests a neutral to slightly positive outlook, with potential for a rebound due to oversold conditions. However, valuation remains a concern due to negative earnings and lack of dividends. The company’s strategic initiatives and market position provide some optimism, but financial stability needs improvement.
To see Spark’s full report on TSE:CL stock, click here.
More about Cresco Labs
Cresco Labs is a leading company in the cannabis industry, known for its branded cannabis products and Sunnyside dispensaries. The company focuses on retail and wholesale operations, maintaining a strong market presence in multiple billion-dollar markets.
Average Trading Volume: 340,613
Technical Sentiment Signal: Hold
Current Market Cap: C$670.8M
See more data about CL stock on TipRanks’ Stock Analysis page.